SPA

F.C.C. TSR Honda France Fights Back to Win Second FIM Endurance World Championship Title

Retrieved on: 
Monday, September 19, 2022

TSR Honda France, running second in the 2022 FIM* Endurance World Championship (EWC), made a comeback to win this year's championship in the final round, the Bol d'Or 2022, held at Circuit Paul Ricard on September 17 - 18.

Key Points: 
  • TSR Honda France, running second in the 2022 FIM* Endurance World Championship (EWC), made a comeback to win this year's championship in the final round, the Bol d'Or 2022, held at Circuit Paul Ricard on September 17 - 18.
  • The team has won the title for the second time, its first in the 2017-2018 season.
  • TSR Honda France kicked off its 2022 campaign with riders Josh Hook (29 years old, Australia), Geno Rea (33 years old, UK) and Mike Di Meglio (24 years old, France) on a Honda CBR1000RR-R FIREBLADE SP.
  • TSR Honda France headed into the final round, the Bol d'Or 2022, second overall, 23 points behind the series leader.

XORTX Completes Positive Pre-Phase 3 Meeting with the US Food and Drug Administration

Retrieved on: 
Monday, September 19, 2022

In advance of this meeting, XORTX submitted a Pre-Phase-3 Briefing Package to the FDA on Thursday, July 28, 2022 and received responses from, and responded to the FDA prior to the meeting.

Key Points: 
  • In advance of this meeting, XORTX submitted a Pre-Phase-3 Briefing Package to the FDA on Thursday, July 28, 2022 and received responses from, and responded to the FDA prior to the meeting.
  • These key milestones and secondary pharmacokinetics modeling of the data from the Companys XRx-008 program well positioned XORTX for in-depth discussions during the Pre-Phase 3 meeting with the FDA.
  • As a result of minimal concerns by the FDA, the focus of the meeting was on optimizing trial design.
  • Based on the discussion, XORTX believes it is well-position to complete a successful, single registration phase 3 clinical trial and associated considerations.

Sumo Logic Opens New Fast Lanes to Power Modern, Digital Business

Retrieved on: 
Tuesday, September 13, 2022

Since its initial launch a year ago, Sumo Logic Real User Monitoring (RUM) has helped hundreds of customers innovate.

Key Points: 
  • Since its initial launch a year ago, Sumo Logic Real User Monitoring (RUM) has helped hundreds of customers innovate.
  • Sumo Logic RUM now captures and displays these metrics out of the box, on overview dashboards for document load action types.
  • Sumo Logic, Inc. (NASDAQ: SUMO) empowers the people who power modern, digital business.
  • Sumo Logic is a trademark or registered trademark of Sumo Logic in the United States and in foreign countries.

NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 24th Annual Global Investment Conference

Retrieved on: 
Thursday, September 8, 2022

RADNOR, Pa., Sept. 8, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced its Chief Executive Officer, Stephen Willard, and other executive leaders will be presenting an update to the company's business at the H.C. Wainwright & Co. 24th Annual Global Investment Conference.

Key Points: 
  • The only FDA-approved treatment for patients with bipolar depression and acute suicidal ideation & behavior (ASIB) remains electroconvulsive therapy (ECT).
  • Conventional antidepressants can increase the risk of suicide in certain patients; hence their labels contain a warning to that effect.
  • NRx Pharmaceuticals is led by executives who have held leadership roles at Lilly, Pfizer, and Novartis as well as major investment banking institutions.
  • This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S.

Systems Planning and Analysis Acquires ORCA Division of Metron

Retrieved on: 
Wednesday, September 7, 2022

ALEXANDRIA, Va., Sept. 6, 2022 /PRNewswire/ -- Systems Planning and Analysis (SPA), Inc., a leading provider of strategic advisory services, has acquired the Operations Research and Cyber Analysis (ORCA) division of Metron.

Key Points: 
  • ALEXANDRIA, Va., Sept. 6, 2022 /PRNewswire/ -- Systems Planning and Analysis (SPA), Inc., a leading provider of strategic advisory services, has acquired the Operations Research and Cyber Analysis (ORCA) division of Metron.
  • In addition to operations research, ORCA specializes in systems of systems engineering, model-based system engineering, and digital engineering processes for the US Navy and other important National Security clients.
  • SPA will continue to run ORCA as a division based in San Diego, CA, led by Jeff Monroe, Coni Ratonel, and Matt Norton, longtime ORCA management teammates.
  • Systems Planning and Analysis, Inc. is a premier international provider of innovative, leading-edge solutions in support of complex National Security programs and defense priorities.

Systems Planning & Analysis, an Arlington Capital Portfolio Company, Acquires the Operations Research & Cyber Analysis (“ORCA”) Unit of Metron

Retrieved on: 
Tuesday, September 6, 2022

ORCA specializes in operations research, systems of systems engineering, model-based system engineering, and digital engineering processes for the Navy and other marquee national security customers.

Key Points: 
  • ORCA specializes in operations research, systems of systems engineering, model-based system engineering, and digital engineering processes for the Navy and other marquee national security customers.
  • ORCA and SPAs capabilities are highly complementary and will allow the combined organization to efficiently deliver continued innovation to our national security customers.
  • Arlington Capital Partners is a Washington, DC-based private equity firm that is currently investing out of Arlington Capital Partners V, L.P., a $1.7 billion fund.
  • Metron, Inc. is a scientific consulting and research firm dedicated to solving challenging technical problems primarily for national security.

Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration

Retrieved on: 
Tuesday, September 6, 2022

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today provided an update on its tebipenem HBr program following the receipt of minutes from a recent Type A meeting with the U.S. Food and Drug Administration (FDA), discussing steps required for resubmission of the New Drug Application (NDA) for tebipenem HBr for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO) today provided an update on its tebipenem HBr program following the receipt of minutes from a recent Type A meeting with the U.S. Food and Drug Administration (FDA), discussing steps required for resubmission of the New Drug Application (NDA) for tebipenem HBr for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis.
  • We are pleased to have found common ground with the FDA on the regulatory path forward for tebipenem HBr, said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics.
  • With this clarity, we are better positioned to advance the program as we work to establish and nurture external partnerships for further development.
  • However, while Spero may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Delfin Midstream and Devon Energy Enter into LNG Export Partnership

Retrieved on: 
Monday, September 5, 2022

HOUSTON, Sept. 05, 2022 (GLOBE NEWSWIRE) -- Delfin Midstream Inc. (Delfin) and Devon Energy Corporation (NYSE: DVN) (together with certain of its operating subsidiaries, collectively, Devon) today announced that they have entered into a liquefied natural gas (LNG) export partnership that includes an executed Heads of Agreement (HOA) for long-term liquefaction capacity and a pre-Financial Investment Decision (FID) strategic investment by Devon in Delfin.

Key Points: 
  • HOUSTON, Sept. 05, 2022 (GLOBE NEWSWIRE) -- Delfin Midstream Inc. (Delfin) and Devon Energy Corporation (NYSE: DVN) (together with certain of its operating subsidiaries, collectively, Devon) today announced that they have entered into a liquefied natural gas (LNG) export partnership that includes an executed Heads of Agreement (HOA) for long-term liquefaction capacity and a pre-Financial Investment Decision (FID) strategic investment by Devon in Delfin.
  • We are delighted to execute this agreement with Devon, representing a truly strategic partnership between a U.S. producer and a liquefaction provider, said Dudley Poston, Delfin CEO.
  • Delfin is a leading LNG export infrastructure development company utilizing low-cost Floating LNG technology solutions.
  • Delfin is the parent company of Delfin LNG LLC (Delfin LNG) and Avocet LNG LLC.

Zimmer Biomet and Surgical Planning Associates Announce Exclusive Multi-Year Co-Marketing Agreement for HipInsight™ Mixed Reality System for Total Hip Replacement

Retrieved on: 
Thursday, September 1, 2022

WARSAW, Ind., Sept. 1, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced an exclusive, multi-year co-marketing agreement with Surgical Planning Associates, Inc. to commercialize HipInsight, the first FDA-cleared mixed reality navigation system for total hip replacement.

Key Points: 
  • WARSAW, Ind., Sept. 1, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced an exclusive, multi-year co-marketing agreement with Surgical Planning Associates, Inc. to commercialize HipInsight, the first FDA-cleared mixed reality navigation system for total hip replacement.
  • "This collaboration enables us to offer surgeons a sophisticated and proven mixed reality-based visualization tool customized for exclusive use with our hip implant portfolio."
  • "We're proud to partner with Zimmer Biomet, a leader in joint arthroplasty, to co-market HipInsight for their portfolio of hip implant systems," said Stephen B. Murphy, M.D., founder of Surgical Planning Associates.
  • A pioneer in the fields of surgical planning and computer-assisted joint reconstruction, SPA is privately held and based in Boston.

Global Dual Interface Payment Card Market (2022 to 2030) - Size, Share & Trends Analysis Report

Retrieved on: 
Thursday, September 1, 2022

DUBLIN, Sept. 1, 2022 /PRNewswire/ -- The "Global Dual Interface Payment Card Market Size, Share & Trends Analysis Report by Type (Plastic, Metal), by End-use (Retail, Healthcare, Transportation, Hospitality), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 1, 2022 /PRNewswire/ -- The "Global Dual Interface Payment Card Market Size, Share & Trends Analysis Report by Type (Plastic, Metal), by End-use (Retail, Healthcare, Transportation, Hospitality), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global dual interface payment card market size is expected to reach USD 23.66 billion by 2030, growing at a CAGR of 16.2% from 2022 to 2030.
  • This partnership was aimed at launching a contactless debit card along with a credit line by leveraging dzcard's dual interface EMV debit card.
  • The outbreak of COVID-19 played a vital role in driving the growth of the dual interface payment card market.